API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.globenewswire.com/news-release/2024/06/06/2894720/33240/en/Emergent-BioSolutions-Continues-Driving-Progress-Against-the-Opioid-Epidemic-Recognizes-National-Naloxone-Awareness-Day.html
https://www.reuters.com/business/healthcare-pharmaceuticals/drugmaker-amneal-agrees-270-million-us-opioid-settlement-2024-05-03/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217992
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213573
https://www.globenewswire.com/news-release/2024/03/28/2853976/33240/en/Emergent-BioSolutions-Continues-to-Broaden-Access-Awareness-and-Availability-of-NARCAN-Nasal-Spray-to-Help-Save-Lives-from-the-Ongoing-Opioid-Crisis.html
https://www.globenewswire.com/news-release/2023/08/30/2734110/33240/en/Emergent-BioSolutions-NARCAN-Nasal-Spray-Launches-Over-the-Counter-Making-it-Possible-for-Everyone-to-Help-Save-a-Life-from-an-Opioid-Overdose-Emergency.html
https://www.prnewswire.com/news-releases/wexler-boley--elgersma-llp-miller-law-llc-hilliard-shadowen-llp-motley-rice-llc-and-spector-roseman--kodroff-pc-announce-a-30-million-class-action-settlement-for-those-who-may-have-purchased-or-provided-reimbursement-for--301910202.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214737
https://endpts.com/otc-naloxone-nasal-spray-to-cost-about-as-much-as-the-brand-name-prescription-version/
https://www.prnewswire.com/news-releases/orexo-wins-patent-litigation-for-zubsolv-in-the-us-301868534.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-7-2023-80553.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-naloxone-hydrochloride-68321.pdf
https://www.globenewswire.com/news-release/2023/03/31/2639055/0/en/Heart-to-Heart-CPR-Now-Offering-Free-Naloxone-Kits-and-Opioid-Response-Training-to-Communities-Most-in-Need.html
https://www.fiercepharma.com/manufacturing/emergent-makes-history-first-fda-nod-over-counter-naloxone
https://www.fiercepharma.com/pharma/ahead-next-months-fda-decision-emergent-aces-adcom-over-counter-narcan
https://endpts.com/should-narcan-spray-be-sold-over-the-counter-fda-poses-potential-packaging-changes/
https://www.fiercepharma.com/pharma/orexo-leveraging-drug-delivery-tech-seeks-fda-approval-nasal-high-dose-opioid-rescue
https://www.prnewswire.com/news-releases/harm-reduction-therapeutics-new-drug-application-for-rivive-over-the-counter-naloxone-nasal-spray-accepted-and-granted-priority-review-by-fda-301710002.html
https://www.biospace.com/article/releases/emergent-biosolutions-announces-u-s-fda-acceptance-and-priority-review-of-supplemental-new-drug-application-for-over-the-counter-narcan-naloxone-hcl-nasal-spray/
https://www.globenewswire.com//news-release/2022/12/06/2568056/33240/en/Emergent-BioSolutions-Announces-U-S-FDA-Acceptance-and-Priority-Review-of-Supplemental-New-Drug-Application-for-Over-the-Counter-NARCAN-naloxone-HCl-Nasal-Spray.html
https://www.wsj.com/articles/opioid-overdose-naloxone-over-the-counter-11669859905
https://www.prnewswire.com/news-releases/naxswab-otc-novel-naloxone-nasal-swab-demonstrates-faster-absorption-and-higher-early-exposures-against-other-naloxone-products-in-clinical-study-301691438.html
https://www.prnewswire.com/news-releases/fda-announces-preliminary-assessment-that-certain-naloxone-products-have-the-potential-to-be-safe-and-effective-for-over-the-counter-use-301678741.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-9-2022-56129.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214792
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216624
https://www.prnewswire.com/news-releases/over-the-counter-naloxone-one-step-closer-as-harm-reduction-therapeutics-initiates-a-rolling-submission-of-its-new-drug-application-nda-to-us-food-and-drug-administration-for-rivive-3-0-mg-intranasal-naloxone-for-emergency--301645959.html
https://www.fda.gov/news-events/fda-voices/fda-issues-new-guidance-help-facilitate-availability-naloxone-prevent-opioid-overdoses-and-reduce
https://www.raps.org/news-and-articles/news-articles/2022/9/fda-exempts-naloxone-distribution-from-dscsa-track
https://endpts.com/indivior-fails-to-escape-class-action-lawsuit-in-suboxone-case/
https://www.prnewswire.com/news-releases/harm-reduction-therapeutics-signs-commercial-supply-agreement-for-fast-tracked-naloxone-nasal-spray-to-reverse-opioid-overdoses-301603546.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215964
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211951
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212300
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213843
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212756
https://www.globenewswire.com/news-release/2022/04/27/2430661/37234/en/Opiant-Pharmaceuticals-Announces-Positive-Topline-Results-from-Head-to-Head-Pharmacodynamic-Study-Comparing-OPNT003-Nasal-Nalmefene-to-Nasal-Naloxone.html
https://www.statnews.com/pharmalot/2022/04/13/bluebird-gene-therapy-blood-disorder/
https://endpts.com/purdue-shells-out-a-little-more-cash-for-a-non-profit-biotech-working-on-naloxone-otc-nasal-spray/